US2021009681A1PendingUtilityA1
Therapeutic DLL4 Binding Proteins
Est. expiryMar 2, 2030(~3.6 yrs left)· nominal 20-yr term from priority
C07K 2317/76A61K 2039/505C07K 2317/24C07K 14/475C07K 16/24A61K 48/00C07K 14/435C07K 16/28A61K 38/18C07K 2317/73C07K 2317/92C07K 14/54C07K 16/22A61K 39/395A61K 39/3955A61K 38/17A61K 45/06C07K 16/18A61P 35/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A binding protein capable of binding DLL4, comprising at least one amino acid sequence selected from the group of amino acid sequences consisting of SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, and SEQ ID NO:164.
2 .- 117 . (canceled)Join the waitlist — get patent alerts
Track US2021009681A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.